Vertex Pharmaceuticals VRTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.34B+9.7% | $3.95B— | —— | —— | —— | ||
| $217.3M+3.6% | $209.8M+4.6% | $200.6M+0.4% | $199.8M-1.1% | $202.1M-2.5% | ||
| $686.2M0.0% | $685.9M-1.5% | $696.1M+1.5% | $685.8M+1.9% | $672.7M-3.7% | ||
| $137.9M-60.3% | $347.3M— | —— | —— | —— | ||
| $454.8M-13.2% | $524.2M-11.8% | $594.3M-8.0% | $645.7M+6.9% | $604.3M+16.8% | ||
| $46.2M+25.5% | $36.8M+433% | $6.9M-93.6% | $108.3M+43.3% | $75.6M+52.7% | ||
| $149.6M+0.7% | $148.5M— | —— | —— | —— | ||
| $4.24B+16.8% | $3.63B+20.6% | $3.01B+82.9% | $1.65B+152% | -$3.18B-18.1% | ||
| $530.3M+21.2% | $437.6M+14.9% | $380.8M+9.8% | $346.7M+28.4% | $270M-9.3% | ||
| $7.26B+13.4% | $6.4B-12.7% | $7.32B-0.5% | $7.36B+13.5% | $6.49B-12.8% | ||
| -$1.32B-39.8% | -$945.4M+36.1% | -$1.48B+13.5% | -$1.71B-1.2% | -$1.69B+55.2% | ||
| $1.93B-4.4% | $2.02B-12.5% | $2.31B+49.5% | $1.54B+4.9% | $1.47B+25.1% | ||
| $327.9M-11.4% | $369.9M-1.3% | $374.7M+2.0% | $367.4M-16.9% | $442M+9.1% | ||
| -$2.12B+6.3% | -$2.26B+12.2% | -$2.58B-42.4% | -$1.81B+0.5% | -$1.82B-21.6% | ||
| $24.2M-74.5% | $95M+135% | $40.4M-36.1% | $63.2M+1,706% | $3.5M+108% | ||
| $853.7M+55.3% | $549.8M+307% | -$266.1M— | —— | —— | ||
| $12.9M+4.0% | $12.4M+2.5% | $12.1M-28.8% | $17M-26.7% | $23.2M-23.9% | ||
| $0-100% | $379M0.0% | $379M0.0% | $379M0.0% | $379M— | ||
| -$94.5M+19.2% | -$116.9M— | —— | —— | —— | ||
| $194.5M-50.9% | $396M+27.7% | $310M— | —— | —— | ||
| -$75.9M+36.8% | -$120.1M-5.9% | -$113.4M+26.8% | -$155M-103% | -$76.5M-8,400% | ||
| $20.2M-20.8% | $25.5M-37.0% | $40.5M-16.7% | $48.6M-18.0% | $59.3M+9.8% | ||
| $6.47B+9.7% | $5.9B-5.9% | $6.27B+3.6% | $6.05B+12.2% | $5.39B+20.8% | ||
| $138M+8.1% | $127.7M+18.2% | $108M-0.5% | $108.5M-5.2% | $114.4M-0.2% | ||
| $3.8M+2.7% | $3.7M+5.7% | $3.5M+6.1% | $3.3M+50.0% | $2.2M-64.5% | ||
| $1.46B-6.5% | $1.57B+8.1% | $1.45B+16.1% | $1.25B+1.3% | $1.23B+13.8% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $3.71B+16.2% | $3.19B+20.6% | $2.65B+102% | $1.31B+138% | -$3.44B-15.4% | ||
| $3.71B+16.2% | $3.19B+20.6% | $2.65B+102% | $1.31B+138% | -$3.44B-15.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Vertex Pharmaceuticals generate?
- Vertex Pharmaceuticals (VRTX) generated $4.2B in operating cash flow over the trailing twelve months.
- What is Vertex Pharmaceuticals's free cash flow?
- After $530.3M of capital expenditures, Vertex Pharmaceuticals's free cash flow was $3.7B over the trailing twelve months, up 207.9% year over year.
- Where does Vertex Pharmaceuticals's cash flow data come from?
- Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
